Stocks

Meta (META) remains a high-conviction core holding for a 2026 horizon, with the company’s pivot into AI-powered hardware and superior ad-targeting efficiency positioning it to outperform. Netflix (NFLX) is a strong buy-on-weakness opportunity as it scales its advertising business to a projected $3 billion by 2026 and expands into live sports and gaming. Investors should avoid Adobe (ADBE) and Salesforce (CRM) for now, as these legacy software giants face intense pricing pressure from cheaper competitors and unproven AI adoption. Be extremely cautious of "AI rebranding" pumps in struggling micro-cap stocks like Allbirds (BIRD), which signal bubble-like behavior rather than long-term value. Maintain a long-term perspective through current market volatility, focusing on "Attention Aggregators" while ignoring short-term geopolitical noise.

Investors should consider Amazon (AMZN) as a core AI infrastructure play following its massive Anthropic partnership, which guarantees long-term demand for AWS and custom Trainium chips. In the semiconductor space, ARM Holdings (ARM) is a top pick for data center growth, while Marvell (MRVL) offers significant upside through its emerging partnership with Google. Apple (AAPL) presents a long-term opportunity to buy on leadership-change weakness as the company shifts focus toward hardware innovation under new CEO John Ternus. For broader market exposure, the S&P 500 remains resilient despite geopolitical tension, with analysts eyeing a potential surge toward 8,600 if a ceasefire is reached. Avoid chasing speculative "meme" stocks like Avis (CAR) or Beyond Meat (BYND), as these parabolic moves are driven by high-risk short squeezes rather than fundamental value.

Hims & Hers Health (HIMS) is currently a high-conviction growth play, with analysts suggesting the stock remains undervalued at $31–$32 despite recent volatility. Investors should look toward a long-term 2029 revenue target of $6.5 billion, driven by the company's expansion into the massive GLP-1 weight loss and peptide markets. For those seeking Bitcoin exposure with less operational complexity than telehealth, MicroStrategy (MSTR) remains a top-three recommended vehicle for tracking digital asset growth. Expect Tesla-like price swings in HIMS, as its "no-insurance" model and AI-driven MedMatch technology disrupt traditional pharmacy and healthcare distribution. This "direct-to-consumer" healthcare theme is particularly strong for capturing Gen Z users who prioritize transparent, upfront pricing over traditional insurance co-pays.

Investors seeking leveraged exposure to Bitcoin should prioritize MicroStrategy (MSTR) over traditional ETFs, as the company’s aggressive "BTC Yield" strategy actively increases the amount of BTC held per share. MSTR is currently utilizing its At-The-Market (ATM) equity offering to raise capital at a premium, a move that is accretive to shareholders and could drive a 20% increase in Bitcoin-per-share by year-end. While short-term volatility from recent short-seller attacks may persist for 7 to 10 days, this provides a strategic entry point before the market's focus shifts back to the company's massive capital raises. For Bitcoin itself, expect a period of healthy consolidation and flat price action near the $75,000 level as the market washes out "Extreme Greed" following geopolitical noise. Use any "small down days" in the immediate future to accumulate positions in BTC or MSTR before the next inevitable leg of the rally begins.

Investors should monitor MicroStrategy (MSTR) for a potential catalyst announcement regarding a massive 30,000 BTC purchase, though caution is advised as the stock currently trades at a high 26% premium to its holdings. For those seeking income, STRC is transitioning to a semi-monthly dividend schedule to reduce price volatility and combat negative market sentiment. Bitcoin (BTC) has established a new base near $78,000, but traders should remain alert to geopolitical tensions in the Middle East which continue to drive short-term price swings. A "barbell strategy" is recommended for balanced exposure, holding BTC directly for growth while using yield-bearing instruments like STRC for cash flow. Avoid chasing the recent 35% rally in MSTR at current levels, as the market enters a "basing" period to solidify recent gains.

Investors should prioritize Bitcoin (BTC) as a primary growth engine, targeting an expected annualized return of 29% as it transitions into a superior corporate treasury collateral. For risk-managed exposure, Strive (ASST) offers a high-upside play on Bitcoin while utilizing a cash buffer to maintain monthly dividends even during market drawdowns. Consider Stretch (STRC) as a "cash-plus" alternative for treasury diversification, offering an 11.5% yield backed by math and code rather than traditional banking IOUs. Monitor MicroStrategy (MSTR) for a potential shift of its $2.25 billion cash reserve into Bitcoin-linked yield instruments as the market for decentralized collateral matures. To mitigate sovereign and banking risk, investors should diversify away from traditional checking accounts toward assets backed by Bitcoin to avoid the vulnerabilities of the zero-reserve fractional banking system.

Investors seeking high-yield income with lower volatility than Bitcoin should consider MicroStrategy preferred-style instruments STRC and SEDA, which currently offer yields of 11.5% and 13% respectively. By holding a combined portfolio of approximately 58% STRC and 42% SEDA, you can create a consistent weekly dividend stream to fund expenses or accelerate compounding. Starting in June, STRC will transition to bi-monthly payouts on the 1st and 15th, while SEDA is expected to pay on the 7th and 21st. This shift to more frequent distributions is designed to reduce price drawdowns on ex-dividend dates, potentially making these assets eligible for "Low Volatility" ETFs like PFF. While these assets are available on platforms like Schwab and Robinhood, investors should note they currently carry a 50% maintenance margin and are not yet treated as "pristine collateral" like Treasuries.

Bitcoin (BTC) is currently viewed as undervalued with a recovery phase just beginning; investors should consider direct exposure or high-conviction proxies like MicroStrategy (MSTR) and Bitcoin Miners to hedge against currency debasement. Hims & Hers Health (HIMS) presents a significant mispricing opportunity with a projected price target in the low $40s by 2025, though investors must be prepared for high volatility. Despite recent stagnation, NVIDIA (NVDA) remains a top pick as its fundamental AI growth outpaces its current stock price, which is still trading below pre-October levels. Tesla (TSLA) and Zoom (ZM) are highlighted as contrarian buys, with TSLA specifically noted for being 15% below recent highs despite its long-term leadership in EV and AI. To navigate the "Black Swan" environment of the 2020s, maintain high cash reserves and strictly avoid margin or complex options to survive sudden, macro-driven market swings.

Meta Platforms (META) is a high-conviction buy as its "AI-driven efficiency" push and headcount reductions aim to expand margins toward a price target recovery of $796. Palantir (PLTR) offers significant upside potential following a massive $12.5 billion FAA contract, as the stock remains nearly 30% below its 52-week highs. Investors seeking high-growth momentum should look to Bitcoin (BTC) as it targets the $77,500 range, or use MicroStrategy (MSTR) as a high-beta leveraged play on the crypto rally. NVIDIA (NVDA) has reclaimed the critical $200 psychological level, making it a key hold ahead of "Super Earnings" day on April 29th. Monitor Salesforce (CRM) and ServiceNow (NOW) for a SaaS sector recovery, while remaining cautious on Adobe (ADBE) due to rising AI competition from tools like Claude.

Investors should consider Zoom Video Communications (ZM) as a high-conviction "hidden" AI play due to its 1.2% ownership stake in Anthropic. At a rumored Anthropic valuation of $800 billion, ZM’s stake would be worth $9.6 billion, representing nearly 40% of its total market cap and making it a more concentrated proxy for AI growth than Amazon (AMZN) or Google (GOOGL). When accounting for its $7.8 billion in cash and the value of its private AI holdings, ZM’s core business is trading at a deep-value EV/EBITDA of 6.6, which analysts suggest provides a significant margin of safety. Monitor developments regarding Anthropic’s "Project Mythos," as its potential to redefine software coding could serve as a massive valuation catalyst for minority shareholders. This creates an asymmetric risk/reward opportunity to buy a profitable, cash-rich company while gaining exposure to a leading contender for the next multi-trillion dollar AI powerhouse.

Meta (META) remains a high-conviction "big bet" for 2026, with Deutsche Bank setting a bullish price target of $920 driven by AI-integrated hardware and seamless social commerce. Amazon (AMZN) is positioned to reach a $300 price target as it scales its satellite internet business via the Globalstar acquisition and gains a competitive edge with its high-performance Graviton chips. While NVIDIA (NVDA) maintains market dominance, investors should monitor rising competition from cloud providers and non-NVIDIA hardware used by firms like Anthropic. Netflix (NFLX) is a strong long-term buy-on-the-dip candidate as it successfully diversifies into gaming and maintains superior pricing power. Conversely, exercise caution with the broader software sector (IGV), as AI disruption poses a fundamental risk to traditional business models like Salesforce and Adobe.

Investors should consider MicroStrategy (MSTR) as a high-beta, leveraged play on Bitcoin, as the stock is currently outperforming the underlying asset by a factor of five. While Bitcoin (BTC) is viewed as significantly undervalued at current levels, watch for institutional adoption from BlackRock (IBIT) and pro-crypto legislation to drive the next leg toward historical highs. For a tactical recovery play, the Strive Bitcoin Income & Growth ETF (STRC) is expected to rebound toward the $100 level early this week as sentiment-driven selling subsides. Maintain core high-conviction positions in growth leaders like Tesla (TSLA) and Hims & Hers Health (HIMS) as the broader market shifts back into a "risk-on" environment. Despite the current rally, avoid chasing the move with new capital and instead wait for market stability to hedge against recurring geopolitical volatility.

The S&P 500 (SPY) is showing historic momentum with a price target of $710, fueled by a massive $175 billion shift from cash into equities. Investors should look to Oracle (ORCL) as a top cloud play, with analysts targeting a move toward the $200–$220 range. Advanced Micro Devices (AMD) is positioned for a breakout toward $300 driven by a global CPU shortage and the upcoming MI450 chip launch. Lower energy prices following the reopening of the Strait of Hormuz provide a tactical entry for travel stocks like Delta (DAL) and Carnival (CCL). While NVIDIA (NVDA) remains the market linchpin above $200, consider trimming profits in "Neo-Cloud" stocks like Nebius (NBIS) following their recent extreme price extensions.

Investors should prioritize Bitcoin (BTC) as the ultimate benchmark for capital, treating its historical annual returns as the "risk-free rate" and avoiding any assets that cannot outperform it. High-performance computing remains a high-conviction sector, with NVIDIA (NVDA) and memory manufacturers benefiting from the endless demand for AI-driven intelligence. For long-term exposure to the next computing frontier, Google (GOOGL) is positioned as a primary leader in the emerging field of Quantum Computing. The longevity and healthcare revolution offers immediate opportunities in AI-driven drug discovery and personalized health platforms like Hims & Hers (HIMS). Finally, monitor SpaceX for a potential future IPO, which will likely signal the start of a massive investment cycle in space manufacturing and asteroid mining.

Investors should consider Hims & Hers Health (HIMS) as a primary play in the direct-to-consumer health space, particularly as it transitions into a leader in the peptide and GLP-1 weight-loss market. Following the acquisition of CS Bio manufacturing assets, the company is vertically integrated to produce proprietary oral peptide pills, which could disrupt the injectable drug market by 2026. While the stock is currently experiencing high volatility due to a short squeeze, any pullbacks toward the $15 level should be viewed as a significant entry point based on fundamental value. Watch for regulatory catalysts regarding Testosterone Replacement Therapy (TRT), as expanded FDA labeling for "low libido" would allow HIMS to aggressively cross-sell to its massive existing customer base. Maintain a long-term perspective on the Weight Loss & Longevity sector, favoring companies like HIMS that bypass traditional insurance "denials" through a subscription-based model.

Investors should consider Oracle (ORCL) as a momentum play, with analysts recently adding to positions at the $178 level to capitalize on the AI infrastructure build-out. While Netflix (NFLX) faces short-term volatility following a weak Q2 guidance and leadership changes, the long-term bull case remains intact with a projected $10 billion ad revenue opportunity and $7 billion in remaining share buybacks. NVIDIA (NVDA) remains a high-conviction hold for the "AI Industrial Revolution" with year-end price targets ranging from $230 to $250, provided macro conditions remain stable. The space sector is seeing a massive rotation into growth names like Rocket Lab (RKLB) and Planet Labs (PL), though investors should be wary of profitability risks and competition from SpaceX. For value-oriented portfolios, ServiceNow (NOW), Adobe (ADBE), and Salesforce (CRM) offer "deep value" through massive free cash flow and aggressive buybacks despite slowing top-line growth.

Investors should consider AMD as it leads the semiconductor sector with a breakout toward $270, targeting a run to $300 ahead of its upcoming earnings. While NVIDIA (NVDA) and TSM show short-term consolidation, the current "breather" in NVDA near $196 offers a strategic entry point for long-term holders. A notable rotation is underway into "beaten-down" SaaS and Fintech names, making Salesforce (CRM) and SoFi (SOFI) high-conviction plays as they benefit from institutional buying and massive call option volume. Rocket Lab (RKLB) has cleared critical resistance at $80, signaling a technical breakout that positions it as the primary public proxy for the growing space economy. For those seeking high-risk, high-reward setups, Hims & Hers (HIMS) remains a top short-squeeze candidate due to its 40% short interest and favorable regulatory shifts.

Investors seeking long-term wealth preservation should prioritize Bitcoin (BTC) as a "hard money" asset, targeting an estimated 29% annualized return over the next two decades. For those requiring stability and income, MicroStrategy Preferred Equity (STRC) offers an 11.5% yield and remains fully collateralized even if BTC prices drop by 75%. High-risk investors can gain leveraged exposure to BTC accumulation through MicroStrategy (MSTR), though they must be prepared for extreme price swings and "brutal" drawdowns. In the healthcare sector, Hims & Hers Health (HIMS) remains a high-conviction play on tech disruption, with the recent approval of peptides serving as a significant growth catalyst. To mitigate "bail-in" risks associated with traditional banking, move capital exceeding FDIC limits out of cash and into "thermodynamically sound" digital assets or prediction markets.

Investors should consider Hims & Hers Health (HIMS) as it transitions from a telehealth platform to a legitimate leader in the high-growth peptide market. The company’s acquisition of a specialized manufacturing facility allows it to scale production of treatments for longevity, recovery, and weight loss while adhering to new FDA safety standards. By legitimizing the "gray market" for substances like BPC-157, HIMS is positioned to capture a massive wave of consumers seeking trusted, US-based sources. The development of "painless needle" technology through their Thrive acquisition further lowers the barrier for entry into injectable therapies. With a shift toward partnering with big pharma giants like Novo Nordisk, the stock presents a strong growth opportunity with potential for a short squeeze as these integrations accelerate.

Investors should consider MicroStrategy (MSTR) as a high-conviction proxy for Bitcoin (BTC), as the stock continues to significantly outperform the underlying digital asset. Current price action suggests the company is actively utilizing its At-The-Market (ATM) equity program, creating a strategic entry point for investors before potential selling pressure subsides. Accumulating shares near the $143 level allows investors to capitalize on Michael Saylor’s strategy of "ATMing into strength" to increase the company's BTC holdings. Treat MSTR not as a traditional software company, but as a specialized fundraising vehicle designed to capture maximum upside from a transitioning Bitcoin-based financial system. Monitor the stock's premium to its BTC holdings closely, as it remains the primary institutional instrument for leveraged exposure to the crypto market.

The S&P 500 ($SPX) has reached the psychological 7,000 milestone, signaling a shift to high greed where investors should maintain bullish exposure while monitoring for signs of overextension. NVIDIA ($NVDA) remains the core AI conviction play, with a sustained close above $200 likely to trigger a fresh momentum rally toward new highs. For software exposure, the IGV ETF is showing a technical breakout, while Palantir ($PLTR) continues to prove that any dip toward its 50-day moving average is a high-conviction buying opportunity. Within the "Neocloud" and infrastructure space, Nebius ($NBIS) is the current sector leader to ride, while Fastly ($FSLY) offers a strategic play on reducing latency for the growing "Agentic AI" trend. Finally, exercise extreme caution with speculative pivots like New Bird AI ($BIRD), as these massive surges often lack fundamental support and serve as indicators of market froth.

Consider buying Oscar Health (OSCAR), which is currently undervalued with a Rule of 40 score of 63 and significant insider buying from the CEO at the $12.00 level. Hims & Hers Health (HIMS) offers a high-conviction play in personalized medicine, leveraging AI to disrupt traditional pharmacy models while maintaining strong growth and profitability metrics. For exposure to a real estate recovery, The Real Brokerage (REAX) is a top pick that is aggressively gaining market share from traditional brokers and is poised to surge if mortgage rates retreat toward 5%. Investors seeking high yield and dominant market positioning should look at Kaspi.kz (KSPI), a regional "super app" with a massive 89 Rule of 40 score and a dividend yield near 9.5%. Focus on these hyper-growth disruptors during market "flash sales" to capture high-quality assets at a significant discount relative to their gross profit growth.

Robinhood (HOOD) is a high-conviction momentum play following the removal of day trading restrictions, with a potential price target of $100–$120 if it maintains its current $82–$85 support level. Watch NVIDIA (NVDA) closely for a clean break above the $200 resistance mark, as heavy call option interest could trigger a massive gamma squeeze and rapid price appreciation. The Quantum Computing sector, specifically IONQ, RGTI, and QBTS, offers high-beta exposure to speculative risk as NVIDIA validates the technology through new partnerships. Investors should consider "on sale" software leaders like Palantir (PLTR) and ServiceNow (NOW), which are rebounding strongly as fears of AI replacing traditional SaaS tools begin to fade. Avoid the recent surge in Allbirds (BIRD), as its pivot to AI infrastructure is highly speculative and likely precedes a dilutive stock offering to raise capital.

The S&P 500 (SPY) is signaling a structural recovery toward all-time highs, supported by record short-covering and strong bank earnings; investors may consider the 2X Long SPY ETF for leveraged upside. NVIDIA (NVDA) remains a top-conviction buy as institutional capital flows into the name, with analysts suggesting it is still undervalued relative to its AI market dominance. Amazon (AMZN) offers a compelling growth play as it targets a $250 milestone, driven by AWS expansion and a potential acquisition of GlobalStar (GSAT), which currently presents a price arbitrage opportunity toward a $90 target. In the crypto space, Bitcoin (BTC) is trending toward the $80,000-$85,000 range, creating a "risk-on" environment that favors high-beta proxies like MicroStrategy (MSTR) and Coinbase (COIN). For speculative value, Iris Energy (IREN) is a timely "buy the dip" opportunity among Bitcoin miners, while Palantir (PLTR) remains the most resilient pick within the volatile AI software sector.

The S&P 500 (SPY) has entered a strong momentum phase, with a break above $700 likely signaling a further rally toward the $725-$750 range through the end of April. Within the AI infrastructure sector, NVIDIA (NVDA) is positioned to reach $206 with a secondary target of $250, while Qualcomm (QCOM) offers a high-value "sleeper" play at a 16x forward PE. Robinhood (HOOD) is a high-conviction momentum trade with a technical path to $90 and a potential long-term stretch to $120 fueled by retail demand and crypto recovery. Amazon (AMZN) is a top breakout candidate following its satellite internet expansion; investors should look for the stock to hold the $240 level to confirm a move higher. In the crypto space, Bitcoin (BTC) clearing $78,500 could trigger a squeeze to $88,000, while Ethereum (ETH) presents a high-probability "layup" trade toward $2,750.

Maintain a long-term core position in Bitcoin (BTC) despite volatility, as institutional absorption from entities like MicroStrategy supports a trajectory toward a long-term $1 million price target. For investors seeking higher beta, MSTR continues to outperform BTC daily, acting as a high-growth "rocket" for the current cycle. Consider the STRC instrument for a more stable 7%–11.5% yield, which offers significant tax-deferral benefits for retirees and residents of high-tax states. Diversify into high-growth Layer 1 blockchains like Solana (SOL) and Hyperliquid (HYPE), which utilize aggressive token-burn mechanisms similar to corporate share buybacks to drive value. Prepare for periodic 40-50% market drawdowns by ignoring short-term "tweet risk" and focusing on the macro tailwinds of regulatory clarity and global GDP growth.

NVIDIA (NVDA) remains a high-conviction leader following its breakout past $190, with its expansion into quantum computing and a strong investment portfolio providing a clear path toward the $194 level and beyond. Amazon (AMZN) is a primary buy as it targets $248–$250 following its acquisition of Global Star (GSAT), with analysts projecting a long-term price target of $290. For Palantir (PLTR), investors should view any recovery toward the $135–$137 range as a confirmation of its sector-leading margin profile and a signal to hold through the software rebound. The surge in Bitcoin (BTC) past $75,000 makes Robinhood (HOOD) and MicroStrategy (MSTR) aggressive "risk-on" plays for those seeking high-beta exposure to the crypto rally. Finally, a potential diplomatic resolution with Iran makes Airlines (AAL, UAL) and Cruise Lines (CCL) attractive tactical buys as falling Oil prices reduce their primary operating costs.